Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury

February 28, 2025 updated by: Chet Moritz, University of Washington
The purpose of this study is to assess the efficacy of non-invasive (transcutaneous) closed-loop electrical spinal cord stimulation for recovery of upper limb function (Aim 1) and spasticity (Aim 2) following spinal cord injury.

Study Overview

Detailed Description

After being informed about the purpose, study timeline, and procedures, all participants giving written informed consent will undergo repeated baseline measurements throughout four weeks, followed by intensive exercise therapy for six weeks.

Next, participants will receive (1) closed-loop stimulation and (2) open-loop stimulation treatment for Aim 1 Section of the study. Stimulation will be delivered non-invasively using skin electrodes on the back of the neck. Each treatment arm will last six weeks. The investigators will determine the order of the treatment arms randomly. For closed-loop stimulation, The investigators will place a sensor on the arm muscles over the skin. This sensor will detect the movement and start the stimulation accordingly.

For Aim 2 Section, intervention arms will consist of (1) transcutaneous stimulation, followed by (2) spasticity-reducing stimulation treatment arms.

There will be a 6-week waiting period between two stimulation arms where participants will not receive any stimulation or exercise therapy. Treatments will last 90 minutes per session, three sessions per week. Overall participation in the study will last ten months: Four weeks baseline + three treatment periods (each will last six weeks) + six weeks waiting period between stimulation treatments + 12 weeks follow-up.

Study Type

Interventional

Enrollment (Estimated)

9

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Fatma Inanici, MD., Ph.D.
  • Phone Number: 206 787 2692
  • Email: finanici@uw.edu

Study Locations

    • Washington
      • Seattle, Washington, United States, 98195
        • Recruiting
        • University of Washington
        • Contact:
        • Contact:
          • Fatma Inanici, MD, PhD
        • Contact:
          • Chet T. Moritz, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. has cervical (C8 or higher), incomplete (American Spinal Cord Injury Impairment Scale - C or D) traumatic spinal cord injury, minimum 1-year post-injury
  2. has difficulty with hand functions in activities of daily living (e.g., dressing, grooming, feeding)
  3. stable medical condition without cardiopulmonary disease or autonomic dysreflexia that would contraindicate participation in upper extremity rehabilitation or testing activities
  4. capable of performing simple cued motor tasks
  5. has ability to attend intervention/functional task training and assessment sessions 3 times/week
  6. has adequate social support to participate in all intervention and baseline/follow-up assessment sessions throughout 40 weeks.
  7. has ability to read and speak English

Exclusion Criteria:

  1. dependent on ventilation support
  2. has implanted stimulator (e.g., pacemaker, vagus nerve stimulator, cochlear implant, etc.) or baclofen pump
  3. has metallic devices and implants in the head (e.g., deep brain stimulators, aneurysm clips/coils, and stents, vagus nerve stimulators)
  4. has a history or current signs/symptoms of syringomyelia (progressive pain, muscle weakness, and/or sensory loss; deterioration of bowel/bladder function)
  5. has autoimmune etiology of spinal cord dysfunction/injury
  6. has received botulinum toxin injections in upper extremity muscles in the prior 6 months
  7. has tendon transfer or nerve transfer surgery in the upper extremity,
  8. taking tizanidine, dantrolene or diazepam
  9. has history of seizures or increased risk for seizures
  10. has history of chronic headaches or migraines
  11. has history of neurologic diseases, such as stroke, multiple sclerosis, traumatic brain injury, etc.
  12. has peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc.)
  13. has rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.)
  14. has significant medical disease; including uncontrolled systemic hypertension with values above 170/100 mmHg; cardiac or pulmonary disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation
  15. has cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention
  16. unhealed fracture, contracture, pressure sore, or frequent urinary tract infections or other illnesses that might interfere with upper extremity rehabilitation or testing activities
  17. has a history of severe allergy (i.e., allergic reaction that could not be treated with antihistaminic medication
  18. has alcohol and/or drug abuse (subject's verbal statement)
  19. has cancer
  20. pregnant (Childbearing potential will be asked at screening, baseline, and every subsequent visit in which the subject would receive transcutaneous spinal cord stimulation and/or Transcranial Magnetic Stimulation whether the participant could be pregnant. Pregnancy will be ruled out by an over-the-counter urine pregnancy test for all females of childbearing potential (1) at the time of enrollment, (2) prior to all sessions that include Transcranial Magnetic Stimulation, and also prior to the intervention phases of (3) closed-loop or (4) open-loop stimulation. Additional pregnancy tests may be performed if there is a concern of pregnancy.)
  21. lack of ability to fully comprehend, cooperate and/or safely perform study procedures in the investigator's opinion/judgment
  22. unable to read and/or comprehend the consent form

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Open-loop Stimulation
Continuous stimulation
Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.
Exercise therapy consists of repeated functional hand and arm movements
Other Names:
  • Intensive exercise therapy
Experimental: Close-loop Stimulation
Intended movement-based stimulation.
Exercise therapy consists of repeated functional hand and arm movements
Other Names:
  • Intensive exercise therapy
Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline- Graded Redefined Assessment of Strength, Sensation, and Prehension version 2
Time Frame: "Repeated measurements once every two weeks throughout the study, an average of 10 months".
Measurement of upper limb strength, sensation, qualitative prehension, and quantitative prehension (range 0-188, higher score mean better outcome)
"Repeated measurements once every two weeks throughout the study, an average of 10 months".
Change from baseline- Capabilities of Upper Extremity Test
Time Frame: "Repeated measurements once every two weeks throughout the study, an average of 10 months".
Measures unilateral and bilateral hand and arm function (range 0-128, higher score mean better outcome)
"Repeated measurements once every two weeks throughout the study, an average of 10 months".
Change from baseline- Grip and Pinch Force
Time Frame: "Repeated measurements once every two weeks throughout the study, an average of 10 months".
Grip and pinch force measurement using a dynamometer (higher score mean better outcome)
"Repeated measurements once every two weeks throughout the study, an average of 10 months".
Change from baseline- Modified Ashworth Scale
Time Frame: "Repeated measurements once every two weeks throughout the study, an average of 10 months".
Clinician administered assessment of spasticity (range 0-4, lower score mean better outcome)
"Repeated measurements once every two weeks throughout the study, an average of 10 months".

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline- International Standards for Neurologic Classification of Spinal Cord Injury - Motor Score
Time Frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Standard manual muscle strength examination (Range 0-100 points, higher score mean better outcome)
"Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Change from baseline- International Standards for Neurologic Classification of Spinal Cord Injury - Sensory Score
Time Frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Standard examination of dermatomal sensation (range 0-224 points, higher score mean better outcome)
"Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Change from baseline- International Standards of Autonomic Functions after Spinal Cord Injury
Time Frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Clinician assessment to document remaining autonomic functions after spinal cord injury
"Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Change from baseline- H-Reflex
Time Frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Electrophysiologic measurement of H-reflex (lower Hmax/Mmax ratio mean better outcome)
"Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Change from baseline- Somatosensory Evoked Potentials
Time Frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Electrophysiologic evaluation of sensory pathways between the brain and the limb (shorter latency mean better outcome)
"Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Change from baseline- Motor Evoked Potentials
Time Frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Electrophysiologic evaluation of motor pathways between the brain and the muscles (higher amplitude mean better outcome)
"Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Change from baseline Spinal Cord Independence Measure Self Report
Time Frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Quantification of the level of independence in daily activities (range 0-100 points, higher score mean better outcome)
"Repeated measurements once every eight weeks throughout the study, an average of 10 months".

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline- World Health Organization Quality of Life Questionnaire
Time Frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Self-reported questionnaire on quality of life (range 0-100 points, higher score mean better outcome)
"Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Change from baseline- Spinal Cord Injury - Functional Index Short-Form
Time Frame: "Baseline"/"At the end of each treatment arm"/"Through study completion"
Patient-reported questionnaire (range 0-100 points, higher score mean better outcome)
"Baseline"/"At the end of each treatment arm"/"Through study completion"
Change from baseline- International Spinal Cord Injury Bowel Function Basic Data Set.v.2.1
Time Frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Patient-reported questionnaire (range 0-47 points, lower score mean better outcome)
"Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Change from baseline- Patient Reported Impact of Spasticity Measure
Time Frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Patient-reported questionnaire (range 0-164 points, lower score mean better outcome)
"Repeated measurements once every eight weeks throughout the study, an average of 10 months".

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Chet Moritz, Ph.D., University of Washington

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 12, 2022

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

June 1, 2026

Study Registration Dates

First Submitted

October 15, 2021

First Submitted That Met QC Criteria

February 23, 2022

First Posted (Actual)

March 7, 2022

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 28, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spinal Cord Injuries

Clinical Trials on Open-loop Stimulation

Subscribe